Despite their promise in the setting of metastatic disease, there is as yet insufficient evidence to conclude on a role for epidermal growth factor receptor (EGFR) inhibitors in locally advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.